Abstract：
BACKGROUND: The role of elafin in the pathophysiology of inflammatory bowel disease (IBD) has not been not elucidated. We aimed to evaluate serum elafin in children with IBD and assess its relationship with disease activity.
METHODS: We enrolled children with IBD in the study group and children with functional abdominal pain in the control group. We evaluated serum elafin using enzyme-linked immunosorbent assay kits.
RESULTS: In children with IBD, serum elafin (mean ± SD: 4.192 ± 1.424 ng/mL) was significantly elevated compared with controls (mean ± SD: 3.029 ± 1.366 ng/mL) (p = 0.0005). Elafin was significantly increased in children in the active phase of IBD (mean ± SD: 4.424 ± 1.449 ng/mL) compared with the control group (p = 0.0003). In IBD remission, only children with ulcerative colitis (mean ± SD: 4.054 ± 1.536 ng/mL) had elevated elafin compared with controls (p = 0.004). ROC analysis revealed that the area under the curve (AUC) of serum elafin was 0.809 while discriminating patients with ulcerative colitis from the control group, and the AUC was 0.664 while differentiating patients with Crohn\'s disease from the control group.
CONCLUSIONS: Serum elafin was found to be elevated in our cohort of children with IBD, depending on disease activity. Serum elafin was increased in the active phases of both ulcerative colitis and Crohn\'s disease, but only in the remission of ulcerative colitis. Elafin appears to be a potential candidate for a biomarker of ulcerative colitis.
METHODS: We enrolled children with IBD in the study group and children with functional abdominal pain in the control group. We evaluated serum elafin using enzyme-linked immunosorbent assay kits.
RESULTS: In children with IBD, serum elafin (mean ± SD: 4.192 ± 1.424 ng/mL) was significantly elevated compared with controls (mean ± SD: 3.029 ± 1.366 ng/mL) (p = 0.0005). Elafin was significantly increased in children in the active phase of IBD (mean ± SD: 4.424 ± 1.449 ng/mL) compared with the control group (p = 0.0003). In IBD remission, only children with ulcerative colitis (mean ± SD: 4.054 ± 1.536 ng/mL) had elevated elafin compared with controls (p = 0.004). ROC analysis revealed that the area under the curve (AUC) of serum elafin was 0.809 while discriminating patients with ulcerative colitis from the control group, and the AUC was 0.664 while differentiating patients with Crohn\'s disease from the control group.
CONCLUSIONS: Serum elafin was found to be elevated in our cohort of children with IBD, depending on disease activity. Serum elafin was increased in the active phases of both ulcerative colitis and Crohn\'s disease, but only in the remission of ulcerative colitis. Elafin appears to be a potential candidate for a biomarker of ulcerative colitis.
摘要：
背景：elafin在炎症性肠病（IBD）的病理生理学中的作用尚未阐明。我们旨在评估IBD儿童的血清埃拉芬，并评估其与疾病活动的关系。
方法：我们将IBD患儿纳入研究组，将功能性腹痛患儿纳入对照组。我们使用酶联免疫吸附测定试剂盒评估了血清elafin。
结果：在患有IBD的儿童中，与对照组(平均值±SD:3.029±1.366ng/mL)相比,血清elafin(平均值±SD:4.192±1.424ng/mL)显著升高(p=0.0005)。与对照组相比，IBD活动期儿童的Elafin显着增加（平均值±SD：4.424±1.449ng/mL）（p=0.0003）。在IBD缓解期,与对照组相比,只有溃疡性结肠炎患儿(平均值±SD:4.054±1.536ng/mL)的elafin升高(p=0.004).ROC分析显示，将溃疡性结肠炎患者与对照组区分开，血清elafin曲线下面积（AUC）为0.809。在区分克罗恩病患者和对照组时，AUC为0.664。
结论：在我们的IBD儿童队列中发现血清elafin升高，取决于疾病活动。血清elafin在溃疡性结肠炎和克罗恩病的活跃期增加，但只有在溃疡性结肠炎的缓解期。Elafin似乎是溃疡性结肠炎生物标志物的潜在候选者。
方法：我们将IBD患儿纳入研究组，将功能性腹痛患儿纳入对照组。我们使用酶联免疫吸附测定试剂盒评估了血清elafin。
结果：在患有IBD的儿童中，与对照组(平均值±SD:3.029±1.366ng/mL)相比,血清elafin(平均值±SD:4.192±1.424ng/mL)显著升高(p=0.0005)。与对照组相比，IBD活动期儿童的Elafin显着增加（平均值±SD：4.424±1.449ng/mL）（p=0.0003）。在IBD缓解期,与对照组相比,只有溃疡性结肠炎患儿(平均值±SD:4.054±1.536ng/mL)的elafin升高(p=0.004).ROC分析显示，将溃疡性结肠炎患者与对照组区分开，血清elafin曲线下面积（AUC）为0.809。在区分克罗恩病患者和对照组时，AUC为0.664。
结论：在我们的IBD儿童队列中发现血清elafin升高，取决于疾病活动。血清elafin在溃疡性结肠炎和克罗恩病的活跃期增加，但只有在溃疡性结肠炎的缓解期。Elafin似乎是溃疡性结肠炎生物标志物的潜在候选者。
